Abstract 981P
Background
Hepatocellular carcinoma (HCC) has a high incidence and mortality worldwide, particularly in Africa and East Asia, due to the widespread hepatitis B and C viral infections (1). Locally advanced HCC is frequently associated with vascular invasion, commonly affecting the portal vein, with an incidence of portal vein tumor thrombosis (PVTT) ranging from 31.4 to 34% (2). PVTT is associated with poor clinical outcomes, including deterioration of hepatic function, tumor dissemination, and shorter overall survival (3). Treatment options for HCC with PVTT are limited. Radiation therapy (RT) has an important role in the management of HCC, from palliative to curative intent. (4).
Methods
Fifty patients with PVTT in HCC were prospectively treated with IMRT using moderately hypofractionated doses. A statistical analysis of the patient's survival and radiotherapy (RT) response was done. Potential prognostic factors for response to RT and survival were assessed.
Results
The median survival for 50 patients was 10 months, with a 1-year survival rate of 36% and a response rate of 36%. Response to treatment, Eastern Cooperative Oncology Group Performance Status (ECOG PS), hepatic focal lesion size, and Child-Pugh score were statistically significant prognostic factors for survival in univariate analysis (P = <0.001, P = 0.001, P = 0.007, and P = <0.001, respectively). Among these factors, Child-Pugh score, ECOG PS, and response to treatment were significant for patient prognosis in multivariable analysis (P = 0.003, P = 0.012, and P = 0.023, respectively).
Conclusions
As patients with PVTT usually have a poor prognosis and short survival, using hypofractionated RT regimens with short-course treatment can improve survival in these patients. RT responders can be elected for treatment with another local treatment modality with a chance for better overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Minia University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18